wakix
bioprojet pharma - pitlisant - narkolepsie - další léky na nervový systém - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - léky na léčbu nemocí kostí - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
jakavi
novartis europharm limited - ruxolitinib (jako fosfát) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastická činidla - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. po polycytemii vera (pv)přípravek jakavi je indikován k léčbě dospělých pacientů s po polycytemii vera, kteří jsou rezistentní na léčbu nebo s intolerancí hydroxymočovina. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
duloxetin +pharma 30mg enterosolventní tvrdá tobolka
+pharma arzneimittel gmbh, graz array - 17225 duloxetin-hydrochlorid - enterosolventní tvrdá tobolka - 30mg - duloxetin
duloxetin +pharma 60mg enterosolventní tvrdá tobolka
+pharma arzneimittel gmbh, graz array - 17225 duloxetin-hydrochlorid - enterosolventní tvrdá tobolka - 60mg - duloxetin
fingolimod +pharma 0,5mg tvrdá tobolka
+pharma arzneimittel gmbh, graz array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod
escitalopram +pharma 10mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 16590 escitalopram-oxalÁt - potahovaná tableta - 10mg - escitalopram
sapropterin dipharma
dipharma arzneimittel gmbh - sapropterin-dihydrochloridu - fenylketonurie - jiné zažívací trakt a produkty metabolismu, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.
agomelatin +pharma 25mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 21421 agomelatin s kyselinou citronovou - potahovaná tableta - 25mg - agomelatin
miglustat dipharma
dipharma arzneimittel gmbh - miglustat - gaucherova choroba - ostatní produkty trávicího traktu a metabolismu - miglustat dipharma je indikován k perorální léčbě dospělých pacientů s mírnou až střední gaucherovou chorobou typu 1. miglustat dipharma může být použit pouze k terapii pacientů, pro které není vhodná enzymatická substituční terapie. miglustat dipharma je indikován pro léčbu progredujících neurologických projevů u dospělých a dětských pacientů s niemann-pickova choroba typu c.